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Howard Swanton, MB BCHIR, MD,yyy Gerry P. McCann, MB CHB, MD*ABSTRACTBACKGROUND The optimal management of patients found to have multivessel disease while undergoing primary
percutaneous coronary intervention (P-PCI) for ST-segment elevation myocardial infarction is uncertain.
OBJECTIVES CvLPRIT (Complete versus Lesion-only Primary PCI trial) is a U.K. open-label randomized study comparing
complete revascularization at index admission with treatment of the infarct-related artery (IRA) only.
METHODS After they provided verbal assent and underwent coronary angiography, 296 patients in 7 U.K. centers were
randomized through an interactive voice-response program to either in-hospital complete revascularization (n ¼ 150) or
IRA-only revascularization (n ¼ 146). Complete revascularization was performed either at the time of P-PCI or before
hospital discharge. Randomization was stratiﬁed by infarct location (anterior/nonanterior) and symptom onset (#3 h
or >3 h). The primary endpoint was a composite of all-cause death, recurrent myocardial infarction (MI), heart failure,
and ischemia-driven revascularization within 12 months.
RESULTS Patient groups were well matched for baseline clinical characteristics. The primary endpoint occurred in 10.0%
of the complete revascularization group versus 21.2% in the IRA-only revascularization group (hazard ratio: 0.45; 95%
conﬁdence interval: 0.24 to 0.84; p ¼ 0.009). A trend toward beneﬁt was seen early after complete revascularization
(p¼ 0.055 at 30 days). Although there was no signiﬁcant reduction in death or MI, a nonsigniﬁcant reduction in all primary
endpoint components was seen. There was no reduction in ischemic burden on myocardial perfusion scintigraphy or in the
safety endpoints of major bleeding, contrast-induced nephropathy, or stroke between the groups.
CONCLUSIONS In patients presenting for P-PCI with multivessel disease, index admission complete revascularization signif-
icantly lowered the rate of the composite primary endpoint at 12 months compared with treating only the IRA. In such patients,
inpatient total revascularization may be considered, but larger clinical trials are required to conﬁrm this result and speciﬁcally
address whether this strategy is associated with improved survival. (Complete Versus Lesion-only Primary PCI Pilot Study
[CvLPRIT]; ISRCTN70913605) (J Am Coll Cardiol 2015;65:963–72) © 2015 by the American College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
FFR = fractional ﬂow reserve
HF = heart failure
IRA = infarct-related artery
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MPS = myocardial
perfusion scintigraphy
N-IRA = non–infarct-related
artery
PCI = percutaneous
coronary intervention
P-PCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
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964P rimary percutaneous coronary inter-vention (P-PCI) is the standard ofcare for patients with ST-segment
elevation myocardial infarction (STEMI).
In up to 30% of such patients, signiﬁcant
stenoses are seen in 1 or more non–infarct-
related arteries (N-IRA) during index angiog-
raphy (1,2).SEE PAGE 973It remains unresolved whether complete
revascularization should be undertaken in
this setting, with historical data providing
conﬂicting evidence on the beneﬁt and
safety of immediate complete revasculariza-
tion versus delayed complete revasculariza-
tion versus revascularization as clinically
required. In registry series, delayed completerevascularization appears to confer beneﬁt, whereas
observational studies to date have generally sug-
gested no beneﬁt and possible harm from immediate
complete revascularization (3,4). The prevailing un-
certainty regarding optimal management has per-
sisted despite the recent PRAMI (Preventive
Angioplasty in Myocardial Infarction) trial, which
demonstrated beneﬁt from complete revasculariza-
tion during the index procedure (5).
CvLPRIT (Complete Versus Lesion-Only Primary
PCI trial) is a U.K. multicenter, randomized, open-label
trial, which set out to test the feasibility, safety, andDepartment of Cardiovascular Sciences, University of Leicester
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revascularization of angiographically signiﬁcant
N-IRA lesions in patients presenting with P-PCI for
STEMI compared with percutaneous coronary inter-
vention (PCI) of the infarct-related artery (IRA) alone.
The hypothesis was that early treatment of signiﬁcant
N-IRA lesions during the index admission would
reduce global ischemic burden and protect against
short- and medium-term recurrent ischemic events.
CvLPRIT and PRAMI ask a similar question but were
initiated independently and with deﬁnitive differ-
ences in trial design.
METHODS
The study was initially conceived and funded as a
pilot trial, with the ﬁrst patient recruited in May 2011
at Glenﬁeld Hospital, and then rolled out to 3 centers
(Leeds General Inﬁrmary, Southampton General
Hospital, and Hareﬁeld Hospital) over the subsequent
6 months. With additional support from the funders,
the study was extended to include 3 more sites
(Kettering General Hospital, Royal Derby Hospital,
and Royal Bournemouth Hospital). The sample size
was determined after the publication of a study by
Politi et al. (6). The study rationale, design, and
power calculation were published previously (7). The
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965Helsinki and approved by the Trent Research Ethics
Committee (reference No. 11/H0405/4) and registered
with International Standard Randomized Controlled
Trial Number (ISRCTN) 70913605.
Patients were recruited from those presenting with
STEMI at 7 U.K. interventional centers. After elec-
trocardiographic conﬁrmation of STEMI, contempo-
rary oral antiplatelet agents were administered
(aspirin 300 mg plus clopidogrel 600 mg loading dose
followed by 75 mg maintenance, prasugrel 60 mg
loading dose and 10 mg daily, or ticagrelor 180 mg
loading dose and 90 mg twice daily). Patients pre-
senting within 12 h of symptom onset were considered
for the trial if they fulﬁlled the initial inclusion
criteria, with no exclusions (Online Table 1). Poten-
tially eligible patients were asked to provide Ethics
Committee–approved verbal assent before coronary
angiography, which was undertaken via the femoral
or radial artery, according to operator preference. If
patients fulﬁlled inclusion criteria after angiography,
and before IRA P-PCI, randomization was undertaken
via a 24-h automated, voice-activated central system.
Patients were randomized to 1 of 2 groups after
P-PCI: either complete revascularization (including all
N-IRAs) or IRA-only treatment. Randomization was
stratiﬁed by infarct location (anterior/nonanterior)
and symptom onset (#3 h or >3 h).
P-PCI was undertaken according to current guide-
line recommendations and operators’ routine practice
and could include aspiration thrombectomy, heparin,
bivalirudin, or glycoprotein IIb/IIIa inhibitor. To
reduce risk of in-stent restenosis, unless clinically
contraindicated, drug-eluting stents (DES) were
recommended for both IRA and N-IRA lesions. If
randomized to complete revascularization, it was
mandated that the IRA be treated ﬁrst. If there were
no clinical contraindications, complete revasculari-
zation was recommended at the same sitting to
reduce multiple vascular punctures, avoid prolonged
hospitalization, and attenuate potential patient
dropout. If the operator decided for clinical reasons
that the procedure be staged, it was mandated that
the N-IRA be treated during the index admission.
Patients were provided with full trial information
within 24 h of PCI and were approached for written
consent to continue in the study. Patients were
treated after the procedure with contemporary
optimal medical therapy. Cardiovascular magnetic
resonance imaging was performed as a pre-speciﬁed
substudy in 205 patients on 1.5-T scanners, as
described previously (8), at a median of 2.9 days
(interquartile range [IQR]: 2.0 to 3.9 days) after P-PCI.
Blinded cardiac magnetic resonance analysis was
undertaken at the University of Leicester corelaboratory, and the results will be analyzed and
reported separately.
CLINICAL OUTCOMES AND FOLLOW-UP. For safety
reasons, all patients were scheduled for myocardial
perfusion scintigraphy (MPS) at 6  2 weeks after
discharge to assess residual ischemia. All MPS exam-
inations were analyzed at a core laboratory, with the
investigator (A.D.K.) blinded to treatment status.
Scans were “nested” (used for study purposes only)
but, for safety reasons, made available to physicians
if the ischemic burden was >20%.
Telephone follow-up was conducted at 6 months
for adverse clinical events. Patients were seen at 9 to
12 months to document major adverse cardiac events
(MACE) comprising all-cause mortality, recurrent MI,
heart failure (HF), and ischemic-driven revasculari-
zation by PCI/coronary artery bypass grafting (CABG).
Pre-speciﬁed secondary endpoints included cardio-
vascular death, individual components of the primary
endpoint, and the safety endpoints of stroke, major
bleeding, and contrast-induced nephropathy.
Clinicians blinded to the randomization group
adjudicated all MACE and safety endpoints (deﬁni-
tions provided in Online Appendix 2). Ethics Com-
mittee permission was given to approach patients
who were randomized in the study but who did not
consent to continued participation, to verify vital
status at 12 months.
Recommended fo l low-up for symptoms. Trial
protocol recommended that chest pain symptoms be
primarily evaluated by noninvasive imaging for
myocardial ischemia, before angiography with or
without PCI. PCI was allowed for ongoing Canadian
Cardiovascular Society class III symptoms (despite
the use of 2 antianginal medications at maximum
tolerated doses) with a negative ischemia test, or if
the patient had been admitted with further acute
coronary syndrome (ACS). If a patient developed
symptoms within 1 month of the 6-week “trial MPS,”
this could be revealed to the supervising phy-
sician. If more than 1 month had passed since trial
MPS, then repeat noninvasive ischemia testing was
recommended.
Tr ia l governance . The sponsor was the University
Hospitals of Leicester National Health Service (NHS)
Trust. The Trial Steering Committee was chaired by
an independent cardiovascular physician (H.S.) and
included 2 independent clinical members and repre-
sentatives of the lay public, the sponsor, and the
funder. An Independent Data Safety and Monitor-
ing Board met regularly and recommended that
the trial continue to completion. The independent
Clinical Trials and Evaluation Unit at the Royal
FIGURE 1 Patient Flow Diagram
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CONSORT (Consolidated Standards of Reporting Trials) diagram of recruitment to the
CvLPRIT study. From 850 patients with ST-segment elevation myocardial infarction, 296
were randomized to receive complete (150) or culprit lesion–only (146) revascularization.
Randomized patients were followed up for 12 months, and analysis was by intention-
to-treat. CABG ¼ coronary artery bypass grafting; CMR ¼ cardiac magnetic resonance;
IRA ¼ infarct-related artery; ITT ¼ intention-to-treat; MACE ¼ major adverse cardiovas-
cular event(s); MPS ¼ myocardial perfusion scintigraphy; MVD ¼ multivessel disease;
N-IRA ¼ non–infarct-related artery; PCI ¼ percutaneous coronary intervention.
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966Brompton & Hareﬁeld NHS Foundation Trust (part of
the National Institute for Health Research–registered
Imperial Clinical Trials Unit) managed the data.
STATISTICAL ANALYSIS. The primary outcome var-
iable, comprising 4 outcomes, was analyzed by time-
to–ﬁrst event survival analysis (log-rank test). The
primary analysis was on an intention-to-treat basis
of all randomized patients according to treatment
group. Kaplan-Meier curves were plotted for ran-
domization to the occurrence of the clinical out-
comes and compared by use of the log-rank test, and
Cox proportional hazard models were ﬁtted to esti-
mate hazard ratios and 95% conﬁdence intervals for
treatment comparisons. The sample size calcula-
tion was based on an estimated primary efﬁcacy
endpoint of average 12-month MACE, from previous
randomized trials, including 12-month cutoff datafrom the study by Politi et al. (6,9,10). On the basis
of these ﬁgures (average 37% MACE in the IRA-only
PCI group vs. 22% in the complete revasculariza-
tion group), for a level 0.05 and 80% power, the
calculated sample size was 144 patients per group.
There were 3 pre-speciﬁed subgroup analyses:
multivessel disease (2 vs. 3), sex, and age (#65 or
>65 years). Continuous data were examined for
normality and expressed as mean  SD or median
(IQR) and compared with the Student t test or
Wilcoxon test as appropriate. Binary event outcomes
were expressed as number (%) of patients, and
comparisons were performed with the chi-square or
Fisher exact test. Two statisticians independently
analyzed all data.
Four of the authors (W.M., D.W., M.F., and A.H.G.)
had full access to the data (after data lock), and all
authors and the trial Steering Committee agreed with
the decision to submit the paper. The funder did not
play any role in data collection, analysis, interpreta-
tion, writing of the manuscript, or the decision to
submit the paper.
RESULTS
We screened 850 patients for inclusion, and 296 were
randomized (146 to IRA only and 150 to complete
revascularization) (Figure 1). Patients in each treat-
ment arm were well matched by demographic and
baseline clinical characteristics, although there was a
nonsigniﬁcant trend for more women in the IRA-only
group. The proportion with 2- or 3-vessel disease,
lesion locations, and N-IRA stenoses >70% were
similar in each group (Table 1).
In the IRA-only arm, 7 patients (5%) crossed over to
receive complete revascularization (Figure 1). In the
complete revascularization group, 11 patients (7%)
received IRA PCI only, with 3 of these referred for
CABG. On the basis of the operator’s clinically driven
decision, 64% of the complete revascularization
group received N-IRA revascularization at the same
procedural session as IRA P-PCI.
Periprocedural details and discharge medications
are shown in Table 2. Although the groups were well
matched, there was increased usage of thrombectomy
catheters in the IRA-only arm. DES use was high in
both groups. The total number of stents implanted
per patient, procedure time, and contrast volume
load were signiﬁcantly higher in the complete revas-
cularization group. Discharge medication was similar
between the 2 groups (Table 2), with very high use of
standard optimal medical therapy. Median length of
stay was similar between the groups: 3 days (IQR: 2 to
4 days; p ¼ 0.828).
TABLE 1 Demographics and Baseline Clinical Characteristics
Complete
Revascularization
(n ¼ 150)
IRA-Only
Revascularization
(n ¼ 146) p Value
Age, yrs 64.6  11.2 65.3  11.9 0.57
Male 128 (85.3) 112 (76.7) 0.06
Treated diabetes 19/147 (12.9) 20/140 (14.3) 0.74
Treated hypertension 54/147 (36.6) 51/140 (36.4) 0.96
Treated hypercholesterolemia 41/147 (27.9) 34/140 (24.3) 0.49
Current smoker 50/146 (34.3) 37/138 (26.8) 0.17
Previous MI 7/147 (4.8) 5/140 (3.6) 0.62
Previous PCI 6/147 (4.1) 3/140 (2.1) 0.50
Killip class II/III on admission 10/147 (6.8) 13/139 (9.4) 0.43
GFR <30 ml/min 1/140 (0.7) 1/137 (0.7) 1.00
Anterior MI 54/150 (36.0) 52/146 (35.6) 0.94
IRA site (selected CASS)
1 Proximal RCA 29 (19.3) 30 (20.5)
2 Mid RCA 23 (15.3) 24 (16.4) 0.82
11 LMS 0 0
12 Proximal LAD 29 (19.3) 31 (21.2)
13 Mid LAD 22 (14.7) 16 (11.0)
18 Proximal Cx 9 (6.0) 13 (8.9)
Other 38 (25.3) 32 (21.9)
N-IRA anatomic site (selected CASS)
1 Proximal RCA 23 (15.3) 22 (15.1)
2 Mid RCA 24 (16.0) 23 (15.8) 0.96
11 LMS 1 (0.7) 2 (1.4)
12 Proximal LAD 27 (18.0) 21 (14.4)
13 Mid LAD 44 (29.3) 49 (33.6)
18 Proximal Cx 20 (13.3) 20 (13.7)
Other 11 (7.3) 9 (6.2)
N-IRA stenoses >70% 131 (87.3) 118 (80.8) 0.12
2-Vessel disease 119 (79.3) 110 (75.3)
3-Vessel disease 31 (20.7) 36 (24.7)
0.41
Symptom to balloon time, min 182 (115-282) 159 (119-265) 0.41
Maximum HS-TnT elevation 985 (629-1,625) 1073 (509-1,824) 0.96
EF (by CMR), % 45.8  9.8
(n ¼ 100)
45.1  9.5
(n ¼ 103)
0.57
Balloon pump 2 (1) 1 (0.6) 1.00
Radial approach 112/146 (76.7) 102/140 (72.9) 0.45
Values are mean  SD, n (%), n/N (%), or median (interquartile range).
CASS ¼ Coronary Artery Scoring System; CMR ¼ cardiac magnetic resonance; Cx ¼ circumﬂex; EF ¼ ejection
fraction; GFR ¼ glomerular ﬁltration rate; HS-TnT ¼ high-sensitivity troponin T; IQR ¼ interquartile range;
IRA ¼ infarct-related artery; LAD ¼ left anterior descending; LMS ¼ left main stem; MI ¼ myocardial infarction;
N-IRA ¼ noninfarct-related artery; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery.
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967ISCHEMIA TESTING. As a safety measure to detect
high residual ischemic burden, 205 patients agreed to
undergo MPS, of whom 203 completed the rest/stress
protocol (100 from the IRA-only group and 103 from
the complete revascularization group), at a median of
7 weeks (IQR: 6.3 to 8.6 weeks) in the complete group
and 6.9 weeks (IQR: 6.3 to 8.3 weeks) in the IRA-only
group. No scans required protocol-mandated
unblinding as a result of ischemic burden >20%.
A full analysis of the MPS data is under way.
CLINICAL OUTCOMES. Among those patients ran-
domized after verbal assent (Central Illustration), the
median follow-up was 364 (IQR: 286 to 365) days.
Nineteen patients were lost to follow-up (Figure 1).
These patients were tracked through a U.K. national
database for their vital status, which conﬁrmed that
none had died.
The primary endpoint is presented as time to ﬁrst
event (Table 3). MACE was signiﬁcantly lower in the
complete revascularization arm (10.0%) than in the
IRA-only arm (21.2%; hazard ratio: 0.45; 95% conﬁ-
dence interval: 0.24 to 0.84; p ¼ 0.009). The indi-
vidual components of the primary endpoint and
cardiovascular mortality were all also lower, although
none were statistically signiﬁcant. The Kaplan-Meier
curves (Figure 2) showed early divergence, with
continuing separation during follow-up. The forest
plot for pre-speciﬁed subanalyses is shown in Online
Figure 1. Kaplan-Meier curves to 30 days are shown in
Online Figure 2.
There was no increase in stroke, major bleed-
ing (all non-CABG related), or contrast-induced
nephropathy in the complete revascularization
group (Table 3). Outcomes were similar between
intention-to-treat groups, per protocol (Online
Table 2), and in the as-treated population (Online
Table 3). There was a signiﬁcant reduction in the
exploratory combined endpoint of all-cause mortal-
ity, recurrent MI, or HF in the complete revasculari-
zation group (p ¼ 0.025) (Online Table 4). There was
a trend to reduced MACE in the population under-
going complete revascularization at the same sitting
as IRA P-PCI compared with those having a staged
procedure (Online Table 5).
SUBSEQUENT REVASCULARIZATION. Reasons for
revascularization are shown in the following text
(excluding patients who underwent revascularization
after presentation with acute MI, which were classi-
ﬁed hierarchically as recurrent MI).
Complete revascu lar i zat ion group (7 events) .
One repeat PCI was symptom driven, 1 followed
admission with troponin-negative ACS, 1 patient
underwent attempted repeat PCI after failed N-IRAPCI at initial P-PCI, 3 underwent CABG after P-PCI to
the IRA only at index admission (2 as outpatients,
1 as urgent inpatient CABG day 3 after P-PCI); and
1 patient had IRA-only revascularization and was
readmitted electively at 6 weeks for further revascu-
larization to the N-IRA.
IRA-only revascu lar i zat ion group (12 events) .
Ten patients underwent PCI for recurrent chest pain
(1 with positive MPS, 5 admitted with troponin-
negative ACS, and a further 4 on the basis of
clinician judgment after optimal [>2] antianginal
therapy). One patient underwent elective N-IRA PCI
TABLE 2 Periprocedural Details, Discharge Medication, and Ischemia Testing
Complete
Revascularization
(n ¼ 150)
IRA-Only
Revascularization
(n ¼ 146) p Value
ASA 141/142 (99.3) 131/135 (97.0) 0.16
Plus clopidogrel 59/144 (41.0) 54/138 (39.1) 0.75
Plus ticagrelor 19/144 (13.2) 18/135 (13.3) 0.97
Plus prasugrel 58/144 (40.3) 64/138 (46.4) 0.30
Plus warfarin 1/147 (0.7) 2/138 (1.5) 0.61
GPI 46/145 (31.7) 44/139 (31.7) 0.99
Bivalirudin 79/139 (56.8) 65/128 (50.8) 0.32
TIMI ﬂow grade 0/1 on arrival 120/147 (81.6) 118/140 (84.3) 0.55
Thrombus aspiration catheter used 93/145 (64.1) 105/140 (75.0) 0.047
DES 141/147 (95.9) 127/140 (90.7) 0.08
Stents per patient 3 (2–4) 1 (1–2) <0.0001
Total procedure time, min 55 (38–74) 41 (30–55.5) <0.0001
Total contrast used, ml 250 (190–330) 190 (150–250) <0.0001
Beta-blocker 137/147 (93.2) 126/135 (93.3) 0.96
ACEI/ARB 142/147 (96.6) 129/135 (95.6) 0.65
Statin 146/146 (100) 133/135 (98.5) 0.14
Aldosterone antagonist 9/147 (6.1) 8/135 (5.9) 0.95
Other antianginal agent 55/147 (37.4) 49/135 (36.3) 0.85
Loop diuretic agent 15/147 (10.2) 17/135 (12.6) 0.53
Values are n/N (%) or median (interquartile range).
ACEI/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ASA ¼ acetylsalicylic acid;
DES ¼ drug-eluting stent(s); GPI ¼ glycoprotein IIb/IIIa inhibitor; IRA ¼ infarct-related artery; TIMI ¼ Throm-
bolysis In Myocardial Infarction.
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968after discharge at the operator’s discretion, and 1
underwent CABG for refractory angina.
DISCUSSION
CvLPRIT has demonstrated that in patients undergo-
ing P-PCI for STEMI, complete revascularization dur-
ing the index admission resulted in a signiﬁcantly
lower MACE rate at 12 months than when only the IRA
was treated, with early separation of clinical event
curves. Although there were numerically fewer events
in individual components of the composite primary
endpoint in the complete revascularization group, the
trial was not powered to detect signiﬁcant differences
inMI or death. After the exclusion of revascularization,
there was a signiﬁcant reduction in the exploratory
combined endpoint of all-cause mortality, recurrent
MI, or HF in the complete revascularization group.
A recent meta-analysis has conﬁrmed that multi-
vessel disease is commonly present among STEMI
patients presenting for P-PCI and has a negative
impact on 30-day mortality (11). However, previous
studies addressing the management of N-IRA lesions
have produced conﬂicting results, as reﬂected in the
2013 American College of Cardiology Foundation/
American Heart Association (12) and 2012 European
Society of Cardiology (13) guidelines (IIIC and IIb
Class C, respectively). These recommendations weremade on the basis of studies that differed in design
and consisted of subgroups of randomized P-PCI trials
(2) or retrospective observational registries (4) and
that suggested that in-hospital complete revasculari-
zation appeared to be associated with worse outcome.
The reason for a trend toward increased mortality
with immediate complete PCI in the nonrandomized
retrospective registry studies is likely attributable to
case selection. As acknowledged by the authors of the
largest published registry from New York, retrospec-
tive studies are intrinsically susceptible to selection
bias, despite attempts to mitigate this by propensity
matching (4). In that registry, multivessel PCI was
performed in only 12.5% of the 4,024 STEMI patients
with multivessel disease. Complete PCI in non-
randomized studies may deﬁne a sicker cohort of
STEMI patients who die of their underlying disease
rather than of a particular treatment strategy. There
are few randomized data that assess the outcomes of
complete revascularization after STEMI in equitable
patient populations. Recently, however, 1 random-
ized trial, PRAMI (5), reported clear clinical beneﬁt in
treating both the IRA and N-IRA at the index proce-
dure. However, this single trial has not resulted in a
widespread change in clinical practice, which makes
the positive results of CvLPRIT particularly relevant,
not least because a review of the data after trial pre-
sentation led to a change in the American College of
Cardiology/American Heart Association recommen-
dation (14).
CvLPRIT data, in particular, showed early separa-
tion of the MACE curves, which in itself warrants
discussion. In general, treatment of a signiﬁcant
stenosis by PCI, especially in stable patients, has been
thought to lead to symptom improvement, rather
than to inﬂuence prognosis. The recently published
network meta-analysis by the European Myocardial
Revascularization Collaboration suggests a potential
mortality beneﬁt as well (15). This intriguing
result calls our understanding of clinically silent
“bystander” disease into question. There is emerging
evidence of pan-coronary inﬂammation (16) and the
presence of multiple unstable coronary plaques (17),
which may explain the higher incidence of recurrent
ACS after STEMI than in patients with stable coronary
disease (18). Paciﬁcation of these bystander plaques
may be proposed as a mechanism of beneﬁt in com-
plete revascularization. However, in our relatively
small study, there were only 2 fewer spontaneous MIs
(type 1) in the complete revascularization group than
in the IRA-only group, which suggests that any effect
of plaque paciﬁcation may be relatively small, but this
should be the focus of mechanistic understanding in
future larger trials.
CENTRAL ILLUSTRATION Complete Versus Lesion-Only Revascularization in Acute MI
Overview of the CvLPRIT trial showing the randomization strategy and main results. CI ¼ conﬁdence interval; CvLPRIT ¼ Complete Versus Lesion-Only Primary PCI trial;
HR ¼ hazard ratio; IRA ¼ infarct-related artery; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction; N-IRA ¼ non–infarct-related artery.
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969The role of fractional ﬂow reserve (FFR) in assess-
ing the importance of the N-IRA in STEMI patients is
contentious and is being compared in a number of
ongoing studies with angiographically guided inter-
vention. In the original FFR study by Dambrink et al.
(19), 40% of nonculprit lesions did not showhemodynamic signiﬁcance (FFR >0.75). In the same
group’s follow-up study (20), FFR-guided interven-
tion resulted in no difference in 3-year MACE.
Although FFR was shown to be safe, its incremental
value over angiographic severity (as used in CvLPRIT)
to pragmatically reﬂect current clinical practice is as
TABLE 3 Clinical Outcomes at 12 Months
Complete
Revascularization
(n ¼ 150)
IRA-Only
Revascularization
(n ¼ 146) HR (95% CI) p Value
Time to ﬁrst event
MACE 15 (10.0) 31 (21.2) 0.45 (0.24–0.84) 0.009
All-cause mortality 2 (1.3) 6 (4.1) 0.32 (0.06–1.60) 0.14
Recurrent MI 2 (1.3) 4 (2.7) 0.48 (0.09–2.62) 0.39
HF* 4 (2.7) 9 (6.2) 0.43 (0.13–1.39) 0.14
Repeat revascularization 7 (4.7) 12 (8.2) 0.55 (0.22–1.39) 0.20
All events
All-cause mortality 4 (2.7) 10 (6.9) 0.38 (0.12–1.20) 0.09
Recurrent MI 2 (1.3) 4 (2.7) 0.47 (0.09–2.59) 0.38
Type 1 0 2
Type 4b 2 2
HF 5 (3.3) 10 (6.9) 0.47 (0.16–1.38) 0.16
Inpatient 3 7 0.56
Post-discharge 2 3
Repeat revascularization 8 (5.3) 16 (11.0) 0.46 (0.20–1.08) 0.07
Safety
CV mortality 2 (1.3) 7 (4.8) 0.27 (0.06–1.32) 0.11
Stroke 2 (1.3) 2 (1.4) 0.95 (0.13–6.77) 0.96
Major bleed 4 (2.7) 7 (4.8) 0.55 (0.16–1.87) 0.34
Contrast-induced
nephropathy
2 (1.4) 2 (1.4) 0.94 (0.13-6.75) 0.95
Values are n (%) for occurrences of both ﬁrst events and total events. Outcomes are shown according to MACE
and individual components of MACE (death, MI, HF, and revascularization) at 12 months. *Of the 13 patients with
failure events, 5 (4 in the IRA-only group and 1 in the complete revascularization group) subsequently died during
the 12-month follow-up.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HF ¼ heart failure; HR ¼ hazard ratio; MACE ¼ major adverse
cardiac event; other abbreviations as in Table 1.
FIGURE 2 Kaplan-Meier Curves
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970yet unproven. Future studies may address the
speciﬁc value of instantaneous FFR.
There was a nonsigniﬁcant trend toward reduced
HF events with complete revascularization. Addi-
tionally, there was an incidence of pre-discharge HF,
which prolonged hospitalization, with double the
number (n ¼ 7) in the IRA-only group compared with
the complete revascularization group (n ¼ 3). Impor-
tantly, there were 5 deaths (4 in the complete
revascularization group and 1 in the IRA-only revas-
cularization group) in patients with HF as a ﬁrst
event, which conﬁrms the poor prognosis of patients
with HF after STEMI. Although these numbers are
small, one could speculate that N-IRA treatment
works through resolving early myocardial stunning/
hibernation. It is well recognized that hibernation
that results from severe coronary artery disease can
contribute to the development of HF. Multiple
studies with different imaging techniques have
shown that revascularization of hibernating myocar-
dium results in improved left ventricular function,
and a meta-analysis suggests this is associated with
improved clinical outcomes (21). As well as pre-
venting hibernation, N-IRA PCI may also improve
myocardial salvage by increasing blood ﬂow to
watershed areas of infarction, which could translate
into improved clinical outcomes.
Importantly, in the context of an open-label study,
the primary endpoint was not driven by differences
in revascularization rates alone. Speciﬁcally, the
reductions in the hazard ratio for death/recurrent MI
and death/MI/HF were at least as great as that for
repeat revascularization and were statistically sig-
niﬁcant for death/MI/HF (Table 3). We acknowledge,
however, that our deﬁnition of MI used was strict,
because recurrent MI had to be driven by symptoms
and was not recorded as being caused by in-
creased periprocedural troponin increases alone (22).
Because of the large enzyme release from the STEMI,
small periprocedural infarcts related to revasculari-
zation of the non-IRA may have been missed. The
frequency and size of these potentially important
type 4b infarcts (23), as well as the effect on
myocardial salvage and hibernating myocardium,
will be addressed in the to-be-published cardiac
magnetic resonance substudy. Further insights
regarding the effect of complete revascularization on
ischemia and how this relates to prognosis will
be gathered from a nuclear imaging substudy that
will be reported separately.
The subgroup analyses suggested beneﬁt in all
subgroups, particularly for women, those older than
65 years of age, and those with double-vessel
disease, although the analyses were limited by the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In 2 randomized
trials reported to date, percutaneous interventions on non–
infarct-related stenotic coronary arteries reduced MACE, which
led to withdrawal of class III practice guideline recommendations
not to treat signiﬁcant non–infarct-related stenoses in patients
with STEMI and multivessel disease undergoing primary
angioplasty.
TRANSLATIONAL OUTLOOK: More clinical trials are needed
to verify whether complete revascularization prevents reinfarc-
tion and mortality, deﬁne the optimal timing of multivessel
revascularization, and determine whether interventional
decisions guided by functional assessment of coronary lesions
improve outcomes.
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971small sample size. Of the 139 patients who had com-
plete revascularization, approximately two-thirds
had N-IRA PCI at the same sitting as the P-PCI. Those
patients with immediate N-IRA PCI showed a strong
trend toward improved clinical outcomes compared
with those undergoing a staged in-hospital procedure.
No ﬁrm conclusions can be drawn, because the
numbers in this arm were small; staging was based on
clinicians’ decisions and was nonrandomized. How-
ever, the early separation of the event curves in
CvLPRIT suggests that a delayed staged outpatient
complete revascularization strategy may not be as
effective as in-hospital treatment.
The high incidence of radial access, DES use,
and optimal secondary preventative medication in
CvLPRIT make it a contemporary P-PCI trial. The
number and severity of treated N-IRA lesions in
CvLPRIT suggest that difﬁcult multivessel disease
cases were included; a small proportion of screened
cases were not considered eligible because of anat-
omy or operator discretion (47 of 850 patients). There
was no increase in any of the secondary safety end-
points, which is reassuring, although further deﬁni-
tive data will be required from larger trials.
Our results are consistent with those seen in the
PRAMI trial (5). CvLPRIT and PRAMI were similar in
general design; both assessed the safety and beneﬁt
of total revascularization intended around the time of
P-PCI. There were, however, important methodolog-
ical differences, which included composite endpoint
deﬁnitions. In general, the results of CvLPRIT and
PRAMI are strikingly similar and add further credence
to the outcome data seen in PRAMI. Particular
features of CvLPRIT included randomization before
IRA PCI was completed and its design, which allowed
clinicians to defer the N-IRA procedure from the
index P-PCI until later during the index admission, if
clinically indicated.
The results of both CvLPRIT and PRAMI provide
randomized data that argue that there may well be an
advantage to undertaking complete revascularization
in STEMI patients. Further large-scale randomized
trials to address the impact of complete revasculari-
zation on hard endpoints (death/recurrent MI), FFR
estimation of N-IRA lesion severity, and the timing of
N-IRA treatment (inpatient vs. outpatient) are criti-
cally needed and ongoing. CvLPRIT and PRAMI have
added to the evidence base regarding that manage-
ment of multivessel disease at P-PCI and provide an
important basis for the robust design of future trials.
STUDY LIMITATIONS. The trial was not powered to
show differences in components of the primary
endpoint, and larger trials powered for death and
MI are needed. Eleven patients in the completerevascularization group and 8 in the IRA-only group
were lost to follow-up; however, none of these pa-
tients died. Case-selection bias cannot be completely
excluded, but because of the very nature of multi-
vessel disease clinical trials in the P-PCI setting, it is
not possible to randomize patients before the results
of the angiogram are known, and such a design is
standard for trials of this type. Repeat revasculariza-
tion may have been inﬂuenced by staff and patient
knowledge of untreated other “signiﬁcant” disease,
although fewer hard endpoints were detected in the
complete revascularization group. Because this was a
pragmatic study, neither intravascular ultrasound nor
FFR was used to assess lesion severity. Future trials
will address their value. Longer-term follow-up
is awaited, although the event curves continue to
diverge at 1 year.
CONCLUSIONS
CvLPRIT has demonstrated that in a population
of patients with STEMI treated by contemporary
P-PCI, in-hospital complete revascularization of
angiographically signiﬁcant N-IRA lesions results in
improved clinical outcomes compared with treatment
of the culprit lesion only. There was no signiﬁcant
reduction in death or MI, and larger clinical trials are
needed to address these speciﬁc endpoints.
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